TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Total Intravenous Versus Inhaled Anesthesia in Endoscopic Sinus Surgery for High-Grade Paranasal Disease
Brief Summary: Utilization of total intravenous anesthesia (TIVA) has been proposed as a method to improve visualization during endoscopic sinus surgery (ESS), largely due to its physiologic decrease in cardiac output without the peripheral smooth muscle relaxation and resultant vasodilation associated with inhaled anesthetics. This may be especially important in cases of advanced inflammatory sinus disease, when visualization may be most compromised. The goal of this study is to improve clinical practice paradigms by evaluating the use of TIVA versus inhaled anesthetic for maintenance of anesthesia in ESS for advanced paranasal sinus disease.


Options:
A: Arm Label: Total Intravenous; Type: EXPERIMENTAL; Interventions: Drug: Propofol | Arm Label: Inhaled Anesthetic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sevoflurane | Intervention Type: DRUG; Name: Propofol; Assigned to Arm(s): Total Intravenous | Intervention Type: DRUG; Name: Sevoflurane; Assigned to Arm(s): Inhaled Anesthetic
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic acid | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sodium Chloride 0.9% | Intervention Type: DRUG; Name: Tranexamic acid; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Sodium Chloride 0.9%; Assigned to Arm(s): 2
C: Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: local group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: systemic group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Arm Label: combined local and systemic; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tranexamic Acid | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): combined local and systemic, control, local group, systemic group
D: Arm Label: Tranexamic Acid; Type: EXPERIMENTAL; Interventions: Drug: Tranexamic Acid | Arm Label: Normal Saline; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline (placebo) | Intervention Type: DRUG; Name: Tranexamic Acid; Assigned to Arm(s): Tranexamic Acid | Intervention Type: DRUG; Name: Normal Saline (placebo); Assigned to Arm(s): Normal Saline

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in the Sylhet, Chittagong and Dhaka Regions of Bangladesh
Brief Summary: The purpose of this study is to assess whether a mobile phone intervention can be effectively used to improve post menstrual regulation contraceptive uptake and continuation in Bangladesh.

The study will consist of two phases: Phase I: A formative phase to understand barriers to post-abortion contraceptive uptake and continuation and the content and modality of messages most appropriate for women in the study areas; and Phase II: An RCT will be conducted to test the effectiveness of the mHealth intervention developed during the formative phase on contraceptive use.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone reminder | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mobile phone reminder | Intervention Type: BEHAVIORAL; Name: Mobile phone reminder; Assigned to Arm(s): Control, Intervention
B: Arm Label: Encouragement Arm; Type: EXPERIMENTAL; Interventions: Other: digital family planning screening and referral service | Arm Label: Control Arm; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: digital family planning screening and referral service; Assigned to Arm(s): Encouragement Arm
C: Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Text Messages; Type: EXPERIMENTAL; Interventions: Other: Daily Text Messages | Intervention Type: OTHER; Name: Daily Text Messages; Assigned to Arm(s): Text Messages
D: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in the Sylhet, Chittagong and Dhaka Regions of Bangladesh
Brief Summary: The purpose of this study is to assess whether a mobile phone intervention can be effectively used to improve post menstrual regulation contraceptive uptake and continuation in Bangladesh.

The study will consist of two phases: Phase I: A formative phase to understand barriers to post-abortion contraceptive uptake and continuation and the content and modality of messages most appropriate for women in the study areas; and Phase II: An RCT will be conducted to test the effectiveness of the mHealth intervention developed during the formative phase on contraceptive use.


Options:
A: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention
B: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS text message; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message | Arm Label: SMS text message + Peer Navigation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message + Peer Navigation | Intervention Type: BEHAVIORAL; Name: SMS text message; Assigned to Arm(s): SMS text message | Intervention Type: BEHAVIORAL; Name: SMS text message + Peer Navigation; Assigned to Arm(s): SMS text message + Peer Navigation
C: Arm Label: WelTel SMS service; Type: EXPERIMENTAL; Interventions: Behavioral: WelTel SMS service | Arm Label: Standard care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: WelTel SMS service; Assigned to Arm(s): WelTel SMS service
D: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mobile phone reminder | Arm Label: Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Mobile phone reminder | Intervention Type: BEHAVIORAL; Name: Mobile phone reminder; Assigned to Arm(s): Control, Intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in the Sylhet, Chittagong and Dhaka Regions of Bangladesh
Brief Summary: The purpose of this study is to assess whether a mobile phone intervention can be effectively used to improve post menstrual regulation contraceptive uptake and continuation in Bangladesh.

The study will consist of two phases: Phase I: A formative phase to understand barriers to post-abortion contraceptive uptake and continuation and the content and modality of messages most appropriate for women in the study areas; and Phase II: An RCT will be conducted to test the effectiveness of the mHealth intervention developed during the formative phase on contraceptive use.


Options:
A: Arm Label: Intervention Group; Type: EXPERIMENTAL; Interventions: Other: Automated text and voice messages | Arm Label: Control Group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Automated text and voice messages; Assigned to Arm(s): Intervention Group
B: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention
C: Arm Label: Usual care / opportunistic screening; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Letter and informational sheet; Type: EXPERIMENTAL; Interventions: Other: Letter and informational sheet | Arm Label: Email; Type: EXPERIMENTAL; Interventions: Other: Email | Arm Label: Phone; Type: EXPERIMENTAL; Interventions: Other: Phone | Arm Label: Multimodal; Type: EXPERIMENTAL; Interventions: Other: Multimodal | Intervention Type: OTHER; Name: Letter and informational sheet; Assigned to Arm(s): Letter and informational sheet | Intervention Type: OTHER; Name: Email; Assigned to Arm(s): Email | Intervention Type: OTHER; Name: Phone; Assigned to Arm(s): Phone | Intervention Type: OTHER; Name: Multimodal; Assigned to Arm(s): Multimodal
D: Arm Label: SmartMoms-Clinic; Type: EXPERIMENTAL; Interventions: Behavioral: SmartMoms | Arm Label: SmartMoms-Phone; Type: EXPERIMENTAL; Interventions: Behavioral: SmartMoms | Arm Label: Physician Directed; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: SmartMoms; Assigned to Arm(s): SmartMoms-Clinic, SmartMoms-Phone

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Using mHealth to Promote Post-Menstrual Regulation Contraceptive Uptake and Continuation in the Sylhet, Chittagong and Dhaka Regions of Bangladesh
Brief Summary: The purpose of this study is to assess whether a mobile phone intervention can be effectively used to improve post menstrual regulation contraceptive uptake and continuation in Bangladesh.

The study will consist of two phases: Phase I: A formative phase to understand barriers to post-abortion contraceptive uptake and continuation and the content and modality of messages most appropriate for women in the study areas; and Phase II: An RCT will be conducted to test the effectiveness of the mHealth intervention developed during the formative phase on contraceptive use.


Options:
A: Arm Label: Clinic group 1; Type: EXPERIMENTAL; Interventions: Behavioral: mHealth messaging | Arm Label: Clinic group 2; Type: EXPERIMENTAL; Interventions: Behavioral: Transport Payments | Arm Label: Clinic group 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: mHealth messaging; Assigned to Arm(s): Clinic group 1 | Intervention Type: BEHAVIORAL; Name: Transport Payments; Assigned to Arm(s): Clinic group 2
B: Arm Label: Short Message Service (SMS) group; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS message | Arm Label: Usual care; Type: PLACEBO_COMPARATOR; Interventions: Other: Usual care | Intervention Type: BEHAVIORAL; Name: SMS message; Assigned to Arm(s): Short Message Service (SMS) group | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Usual care
C: Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: SMS text message; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message | Arm Label: SMS text message + Peer Navigation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: SMS text message + Peer Navigation | Intervention Type: BEHAVIORAL; Name: SMS text message; Assigned to Arm(s): SMS text message | Intervention Type: BEHAVIORAL; Name: SMS text message + Peer Navigation; Assigned to Arm(s): SMS text message + Peer Navigation
D: Arm Label: mhealth intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Mhealth intervention | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Mhealth intervention; Assigned to Arm(s): mhealth intervention

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Double, Blind Placebo-controlled, Randomized Trial to Study Efficacy and Safety of the Viaskin Milk for Treating Milk Induced Eosinophilic Esophagitis in Children
Brief Summary: This is a single-site, double-blind, placebo-controlled, randomized trial to study efficacy and safety of the Viaskin® Milk Patch for children with milk induced Eosinophilic Esophagitis (EoE). 20 subjects will be randomized 3:1 to Viaskin® Milk or placebo patch.


Options:
A: Arm Label: 1; Type: N/A; Interventions: Other: assessment of disease activity using the EEsAI | Arm Label: 2; Type: N/A; Interventions: Other: assessment of disease activity using the EEsAI | Intervention Type: OTHER; Name: assessment of disease activity using the EEsAI; Assigned to Arm(s): 1, 2
B: Arm Label: Part A: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part B: Dupilumab or Placebo; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Part C: Dupilumab; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo, Part C: Dupilumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Part A: Dupilumab or Placebo, Part B: Dupilumab or Placebo
C: Arm Label: Viaskin Milk 500 mcg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Viaskin Milk 500 mcg | Arm Label: Viaskin Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Viaskin Placebo | Intervention Type: DRUG; Name: Viaskin Milk 500 mcg; Assigned to Arm(s): Viaskin Milk 500 mcg | Intervention Type: DRUG; Name: Viaskin Placebo; Assigned to Arm(s): Viaskin Placebo
D: Arm Label: inhaled/swallowed budesonide; Type: EXPERIMENTAL; Interventions: Drug: inhaled/swallowed budesonide | Arm Label: viscous/swallowed budesonide; Type: ACTIVE_COMPARATOR; Interventions: Drug: viscous/swallowed budesonide | Intervention Type: DRUG; Name: inhaled/swallowed budesonide; Assigned to Arm(s): inhaled/swallowed budesonide | Intervention Type: DRUG; Name: viscous/swallowed budesonide; Assigned to Arm(s): viscous/swallowed budesonide

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF AVELUMAB (MSB0010718C) ALONE OR IN COMBINATION WITH PEGYLATED LIPOSOMAL DOXORUBICIN VERSUS PEGYLATED LIPOSOMAL DOXORUBICIN ALONE IN PATIENTS WITH PLATINUM-RESISTANT/REFRACTORY OVARIAN CANCER
Brief Summary: A Phase 3 global study comparing avelumab alone to avelumab plus PLD and to PLD alone to demonstrate that avelumab given alone or in combination with PLD is superior to PLD alone in prolonging Overall Survival in patients with platinum resistant/platinum refractory ovarian cancer.


Options:
A: Arm Label: Cyclophosphamid + Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Cyclophosphamid + Pazopanib
B: Arm Label: avelumab; Type: EXPERIMENTAL; Interventions: Biological: avelumab | Arm Label: avelumab plus pegylated liposomal doxorubicin (PLD); Type: EXPERIMENTAL; Interventions: Biological: avelumab, Drug: PLD | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: BIOLOGICAL; Name: avelumab; Assigned to Arm(s): avelumab, avelumab plus pegylated liposomal doxorubicin (PLD) | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD, avelumab plus pegylated liposomal doxorubicin (PLD)
C: Arm Label: Niraparib monotherapy; Type: EXPERIMENTAL; Interventions: Drug: Niraparib | Arm Label: Niraparib-bevacizumab combination; Type: EXPERIMENTAL; Interventions: Drug: Niraparib, Drug: Bevacizumab | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Niraparib monotherapy, Niraparib-bevacizumab combination | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Niraparib-bevacizumab combination
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Early Initiation of Low-dose Hydrocortisone Treatment for Septic Shock in Adults: a Randomized Clinical Trial
Brief Summary: The purpose of this study : 1）to determine whether hydrocortisone is effective in the treatment of septic shock and 2) to identify the role of timing of low dose hydrocortisone administration in septic shock patients.


Options:
A: Arm Label: Hydrocortisone and fludrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone Fludrocortisone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Controlled; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Hydrocortisone Fludrocortisone; Assigned to Arm(s): Hydrocortisone and fludrocortisone
B: Intervention Type: DRUG; Name: hydrocortisone 200 mg/day; Assigned to Arm(s): N/A
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: saline | Arm Label: hydrocortisone; Type: EXPERIMENTAL; Interventions: Drug: Hydrocortisone | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): hydrocortisone | Intervention Type: DRUG; Name: saline; Assigned to Arm(s): Placebo
D: Arm Label: Hydrocortisone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocortisone | Arm Label: Sterile air filled vial; Type: PLACEBO_COMPARATOR; Interventions: Drug: Sterile air filled vial | Intervention Type: DRUG; Name: Hydrocortisone; Assigned to Arm(s): Hydrocortisone | Intervention Type: DRUG; Name: Sterile air filled vial; Assigned to Arm(s): Sterile air filled vial

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Adults ≥ 65 Years of Age With and Without Zostavax® Vaccination at Least 5 Years Earlier
Brief Summary: The purpose of this study is to evaluate the immunogenicity and safety of GSK Biologicals' HZ/su vaccine in adults ≥ 65 years of age with and without Zostavax® vaccination at least 5 years earlier.


Options:
A: Arm Label: Co-Ad Group; Type: EXPERIMENTAL; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: Herpes Zoster vaccine GSK 1437173A, Biological: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A | Intervention Type: BIOLOGICAL; Name: Herpes Zoster vaccine GSK 1437173A; Assigned to Arm(s): Co-Ad Group, Control Group | Intervention Type: BIOLOGICAL; Name: GSK Biologicals' quadrivalent seasonal influenza vaccine FLU-D-QIV GSK2321138A; Assigned to Arm(s): Co-Ad Group, Control Group
B: Arm Label: GSK1437173A Group; Type: EXPERIMENTAL; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Arm Label: Control Group; Type: ACTIVE_COMPARATOR; Interventions: Biological: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A) | Intervention Type: BIOLOGICAL; Name: GSK Biologicals Herpes Zoster subunit (HZ/su) vaccine (GSK 1437173A); Assigned to Arm(s): Control Group, GSK1437173A Group
C: Arm Label: NBP608; Type: EXPERIMENTAL; Interventions: Biological: NBP608 | Arm Label: Zostavax; Type: ACTIVE_COMPARATOR; Interventions: Biological: Zostavax | Intervention Type: BIOLOGICAL; Name: NBP608; Assigned to Arm(s): NBP608 | Intervention Type: BIOLOGICAL; Name: Zostavax; Assigned to Arm(s): Zostavax
D: Arm Label: GSK1437173A 18-30 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Arm Label: GSK1437173A 50-70 Years Old Group; Type: EXPERIMENTAL; Interventions: Procedure: Blood sampling for assay of persistence of immunogenicity | Intervention Type: PROCEDURE; Name: Blood sampling for assay of persistence of immunogenicity; Assigned to Arm(s): GSK1437173A 18-30 Years Old Group, GSK1437173A 50-70 Years Old Group

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications
Brief Summary: The purpose of this study is to determine if the application of a negative pressure dressing intraoperatively (Prevena; KCI, Inc) to vascular groin incisions decreases the wound complication rate in high risk patients.


Options:
A: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care
B: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection
C: Arm Label: Dry Dressing; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: V.A.C. by K.C.I. | Intervention Type: DEVICE; Name: V.A.C. by K.C.I.; Assigned to Arm(s): Negative Pressure Wound Therapy
D: Arm Label: Negative Pressure Wound Therapy; Type: EXPERIMENTAL; Interventions: Device: Negative pressure wound therapy | Arm Label: Standard dressing; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Negative pressure wound therapy; Assigned to Arm(s): Negative Pressure Wound Therapy

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evaluation of Closed Incision Negative Pressure Device (Prevena) to Prevent Vascular Wound Complications
Brief Summary: The purpose of this study is to determine if the application of a negative pressure dressing intraoperatively (Prevena; KCI, Inc) to vascular groin incisions decreases the wound complication rate in high risk patients.


Options:
A: Arm Label: High Risk - Prevena Care; Type: EXPERIMENTAL; Interventions: Device: Prevena Care | Arm Label: High Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Arm Label: Low Risk - Dry Gauze Dressing Care; Type: ACTIVE_COMPARATOR; Interventions: Device: Dry gauze dressing care | Intervention Type: DEVICE; Name: Prevena Care; Assigned to Arm(s): High Risk - Prevena Care | Intervention Type: DEVICE; Name: Dry gauze dressing care; Assigned to Arm(s): High Risk - Dry Gauze Dressing Care, Low Risk - Dry Gauze Dressing Care
B: Arm Label: Vacuum assisted closure; Type: EXPERIMENTAL; Interventions: Procedure: vacuum assisted closure | Arm Label: Axillary dissection; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Axillary dissection | Intervention Type: PROCEDURE; Name: vacuum assisted closure; Assigned to Arm(s): Vacuum assisted closure | Intervention Type: PROCEDURE; Name: Axillary dissection; Assigned to Arm(s): Axillary dissection
C: Arm Label: Vacuum-assisted closure (VAC); Type: EXPERIMENTAL; Interventions: Device: Vacuum-assisted closure | Arm Label: Standard sterile dressing; Type: ACTIVE_COMPARATOR; Interventions: Device: Standard sterile dressing | Intervention Type: DEVICE; Name: Vacuum-assisted closure; Assigned to Arm(s): Vacuum-assisted closure (VAC) | Intervention Type: DEVICE; Name: Standard sterile dressing; Assigned to Arm(s): Standard sterile dressing
D: Arm Label: Closed Incision Wound vacuum (Prevena); Type: EXPERIMENTAL; Interventions: Device: Closed incision wound vacuum (Prevena) | Arm Label: Routine Wound Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Closed incision wound vacuum (Prevena); Assigned to Arm(s): Closed Incision Wound vacuum (Prevena)

Answer: A